LFB’s plasma-derived biopharmaceuticals

With a commitment to patient safety at the heart of the company, the production of our plasma-derived biopharmaceuticals is carefully managed, from donation at plasma centres right through to final product.

The LFB group owns a chain of plasma collection centres (EUROPLASMA Group). Following the highest quality standards, EUROPLASMA is a member of the Plasma Protein Therapeutic Association (PPTA).* The plasma donated at EUROPLASMA centres is used to make plasma products, notably for the UK.

In addition to donation standards, LFB also includes other steps within our manufacturing processes that meet and exceed European regulatory standards. LFB is at the forefront of safety technology, having incorporated cutting edge techniques such as nanofiltration (which physically removes pathogens) as early as 1995.

* The Plasma Protein Therapeutics Association (PPTA) is a trade association that represents over 450 human plasma collection centres in North America and Europe, as well as the private sector manufacturers of life saving plasma protein therapies. It administers standards programmes that help ensure the quality and safety of plasma collection and manufacturing and protect both donors and patients.

Plasma-derived medicinal products: A 3-step biological safety process from donor to patient